Food and Drug
Administration
Oncologic
Drugs Advisory Committee
June 2, 2006
Briefing Information
Bristol-Myers Squibb Company
The statements contained in this document(s) are those of
the product’s sponsor, not
FDA, and FDA does not necessarily agree with the sponsor’s
statements. FDA has not
made a final determination about the safety or effectiveness
of the product described in
this document.
Bristol-Myers
Squibb Briefing Material for Sprycel
FDA
Disclaimer
Portions of this document have been determined to be exempt
from disclosure under the
Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
These redacted portions will appear as white space on the
screen or on the printed page.
FDA Briefing Material
for Sprycel